BCS1L Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the near-haploid human HAP1 cell line, in which the BCS1L gene has been broadly disrupted via CRISPR/Cas9-mediated gene targeting. This loss-of-function model provides a genetically defined platform for investigating the role of the mitochondrial inner membrane chaperone BCS1L in respiratory chain complex III assembly and oxidative phosphorylation. As a polyclonal population, the product contains a heterogeneous pool of edited cells, enabling robust functional studies without clonal selection.
HAP1 cells are a widely utilized adherent cell line originating from the KBM-7 chronic myeloid leukemia background, notable for their near-haploid karyotype with only a single copy of most chromosomes. This hemizygosity simplifies genetic manipulation by negating the potential for compensatory effects from a second functional allele, ensuring that CRISPR/Cas9-mediated disruption of the single BCS1L locus directly manifests a null phenotype. The haploid nature of HAP1 cells makes them an ideal host for knockout screens and detailed characterization of gene function in a consistent genomic context.
The BCS1L gene encodes an essential mitochondrial chaperone responsible for the incorporation of the Rieske iron-sulfur protein (UQCRFS1) into complex III of the respiratory chain, a critical step in electron transport chain assembly. BCS1L functions downstream of transcriptional regulators such as TFAM, NRF1, and PPARGC1A, and directly interacts with UQCRFS1, LYRM7, UQCRC1, and UQCRC2 to mediate complex III maturation. Disruption of BCS1L blocks UQCRFS1 insertion, leading to destabilized complex III and impaired electron transfer from ubiquinol to cytochrome c, ultimately disrupting ATP synthesis and increasing reactive oxygen species production.
In the HAP1 haploid background, knockout of BCS1L creates a clean loss-of-function model that recapitulates molecular features of mitochondrial complex III deficiency and associated disorders such as GRACILE syndrome, Bj?rnstad syndrome, and Leigh syndrome. Because HAP1 cells lack a backup wild-type allele, the phenotypic consequences of BCS1L disruption??including defective oxidative phosphorylation and altered mitochondrial membrane potential??can be observed without interference from residual protein expression. This cellular context is particularly valuable for dissecting the assembly pathway of complex III and evaluating potential rescuing agents.
These BCS1L knockout cells are suitable for a wide range of applications, including modeling mitochondrial complex III deficiency, functional genomics of respiratory chain disorders, and drug screening for modulators of mitochondrial metabolism. Researchers can employ well-established assays such as western blotting for BCS1L and complex III subunits, Blue native PAGE to assess supercomplex integrity, Seahorse analysis for oxygen consumption rate, ATP quantification, flow cytometry using TMRE to monitor mitochondrial membrane potential, and ROS detection assays. For further experimental customization or technical support, please contact Ascent Research.
